• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter: ustekinumab dose intensification for loss of response-should we re-induce before shortening the dose interval? Author's reply.

作者信息

Kopylov Uri

机构信息

Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel.

出版信息

Aliment Pharmacol Ther. 2020 Aug;52(3):565-566. doi: 10.1111/apt.15892.

DOI:10.1111/apt.15892
PMID:32656845
Abstract
摘要

相似文献

1
Letter: ustekinumab dose intensification for loss of response-should we re-induce before shortening the dose interval? Author's reply.信函：对于应答丧失的患者，乌司奴单抗剂量强化——我们应该在缩短给药间隔之前重新诱导吗？作者回复。
Aliment Pharmacol Ther. 2020 Aug;52(3):565-566. doi: 10.1111/apt.15892.
2
Letter: ustekinumab dose intensification for loss of response-should we re-induce before shortening the dose interval?
Aliment Pharmacol Ther. 2020 Aug;52(3):564-565. doi: 10.1111/apt.15883.
3
Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail. Authors' reply.信函：在抗TNF难治性克罗恩病中选择优特克单抗和维多珠单抗——细节决定成败。作者回复
Aliment Pharmacol Ther. 2020 Aug;52(3):563-564. doi: 10.1111/apt.15888.
4
Letter: propensity score-handle with care. Authors' reply.
Aliment Pharmacol Ther. 2021 Jan;53(2):362-363. doi: 10.1111/apt.16211.
5
Successful treatment of hidradenitis suppurativa in the setting of Crohn disease with combination adalimumab and ustekinumab.阿达木单抗和优特克单抗联合治疗克罗恩病合并化脓性汗腺炎取得成功。
Dermatol Online J. 2019 Sep 15;25(9):13030/qt0hw2w4nr.
6
Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail.信函：在抗TNF难治性克罗恩病中选择优特克单抗和维多珠单抗——细节决定成败。
Aliment Pharmacol Ther. 2020 Aug;52(3):561-562. doi: 10.1111/apt.15862.
7
Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease-results from the ENEIDA registry. Authors' reply.社论：优特克单抗在305例克罗恩病患者中的真实世界短期疗效——来自ENEIDA注册研究的结果。作者回复
Aliment Pharmacol Ther. 2019 Sep;50(5):600-601. doi: 10.1111/apt.15447.
8
Ustekinumab in Pediatric Crohn Disease Patients.优特克单抗用于儿童克罗恩病患者
J Pediatr Gastroenterol Nutr. 2016 Sep;63(3):348-51. doi: 10.1097/MPG.0000000000001146.
9
Ustekinumab IV 6 mg/kg Loading Dose Re-induction Improves Clinical and Endoscopic Response in Crohn's disease: A Case Series.乌司奴单抗静脉注射6mg/kg负荷剂量再诱导改善克罗恩病的临床和内镜反应：病例系列
Am J Gastroenterol. 2018 Apr;113(4):627-629. doi: 10.1038/ajg.2018.22.
10
Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.用于诱导克罗恩病缓解的抗IL-12/23 p40抗体。
Cochrane Database Syst Rev. 2015 May 5(5):CD007572. doi: 10.1002/14651858.CD007572.pub2.